As I was doing due diligence on Spectrum Pharmaceuticals (SPPI), I came across an interesting story. Here's what happened. SPPI was having a bounty year due to selling Fusilev (levo-leucovorin) into a market that was temporarily seeing a shortage of generic leucovorin calcium. Such a shortage ended a few months ago, and that led SPPI to issue a massive revenue warning for 2013. In the process, however, I got to know one of the leucovorin calcium producers: Sagent Pharmaceuticals (SGNT).
And guess what, although SGNT doesn't seem to have much coverage, it does appear to be an interesting company.
Two basic insights
Sagent Pharmaceuticals provides the market with injectable generic drugs. That all by...
Only subscribers can access this article, which is part of the PRO research library covering 3,759 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: